https://www.selleckchem.com/GSK-3.html
When combined with niclosamide or specific STAT3 inhibitor (C188-9), the cytotoxicity and DNA damage response from SN38 (the active metabolite from irinotecan) were significantly enhanced. The sequential exposure of SN38 followed by niclosamide was found to be the most potent treatment sequence for the drug combination. Niclosamide represents a promising candidate for repurposing to potentiate the anticancer activity of chemotherapeutic drugs. Niclosamide represents a promising candidate for repurposing to potentiate the anticancer activity of che
Like
Comment
Share
